PHILADELPHIA — Men taking testosterone therapy had a 29 percent greater risk of death, heart attack and stroke according to a study of a "real world" population of men. An accompanying editorial in JAMA by an endocrinologist with the Perelman School of Medicine at the University of Pennsylvania notes that the mounting evidence of a signal of cardiovascular risk warrants cautious testosterone prescribing and additional investigation.
An estimated 2.9 percent of US men over 40 years old are prescribed testosterone therapy, yet there are limited randomized trial data examining the long term benefits and risks.
A study of patients in the VA system compared 1,223 men taking testosterone with 7,489 men not using testosterone and found a greater percentage of deaths, heart attacks and strokes in the testosterone group. Approximately 1 in 5 men not taking the therapy had such an event, whereas more than 1 in 4 men taking testosterone had a heart attack, stroke, or died over a three year period.
"We do not know if this risk extends to men who are taking testosterone for 'low T syndrome' or younger men taking it for physical enhancement, as there is a lack of long term safety data of testosterone therapy in men," said Anne Cappola, MD, ScM, associate professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism in the Perelman School of Medicine at the University of Pennsylvania. "But the men who were taking testosterone in this study were slightly healthier to begin with, and surprisingly had a higher risk of catastrophic events."
Dr. Cappola notes that additional information from the ongoing T Trial - a randomized trial of 800 men aged 65 and older with diminished walking ability, interest in sex, energy, memory or iron levels in blood who will receive testosterone gel or placebo for one year - may provide important guidance to older men who meet current recommendations for testosterone therapy. Until then, Dr. Cappola notes that "prescribers and patients should be wary."
Editorial notes: Dr. Cappola is an Associate Editor for JAMA. The T Trial is a multicenter trial funded by the National Institutes of Health and led by Peter Snyder, MD, professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism in the Perelman School of Medicine at the University of Pennsylvania.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.
Department of Communications
For Patients and the General Public: